Pune: An 18-year-old girl suffered serious injuries after being attacked with a koyta (sickle) in the Hinjewadi area on Saturday. The Hinjewadi police.

A 70-year-old man undergoing a leg amputation was diagnosed with a rare combination of acquired hemophilia A and Factor XII ...

Get the Latest City News and Metro News Headlines on Indian Express. Grab the Exclusive News Headlines from Top most Indian Cities.

"Fear Factor" is returning to screens, and it’s looking very different from the last time you saw it. Officially called "Fear Factor: The Next Chapter", the extreme competition series is adding a ...

A new study found that both lupus anticoagulant (LA) and anti-β2 glycoprotein I (β2GPI) IgG/IgM antibodies had predictive value for adverse pregnancy outcomes and complications, specifically ...

Chris is a writer and editor with over 10 years of experience covering games and has a bachelor's degree in History from the University of Central Lancashire. He's mainly focused on guides, but has ...

Grace is a Guides Staff Writer from New Zealand with a love for fiction and storytelling. Grace has been playing games since childhood and enjoys a range of different genres and titles. From pick your ...

Abiotic Factor is an unforgettable interdimensional odyssey with you and your closest friends. PC Gamer's got your back Our experienced team dedicates many hours to every review, to really get to the ...

Andembry (garadacimab-gxii) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in adults and adolescents. During an HAE attack, swelling under the skin happens in different ...

Andembry is the first monthly Factor XIIa inhibitor for the prevention of HAE attacks and will be available to patients “before the end of June,” CSL announced. The FDA on Tuesday signed off on CSL’s ...

Credit: CSL. The approval was supported by data from the randomized, double-blind, phase 3 VANGUARD trial. Andembry is expected to be available before the end of June. The Food and Drug Administration ...

Garadacimab-gxii is the first FDA-approved factor XIIa inhibitor for hereditary angioedema, offering a once-monthly prophylactic treatment option. The VANGUARD trial showed an 87% reduction in HAE ...